EATONTOWN, N.J., May 20 /PRNewswire/ -- Roberts Pharmaceutical Corporation
(Amex: RPC) today announced additions to its U.S. and Canadian management
staffs. The Company also said it has organized its U.S. sales and marketing
department into separate Rx and Consumer Products Divisions.
"With the recent purchases of pharmaceutical manufacturing and
distribution facilities plus the sale of our contract research business, we
are positioned for growth as a fully integrated pharmaceutical company," said
John T. Spitznagel, Roberts' President and CEO. "The organizational
announcements made today are in line with this strategy of focusing resources
and management talents on our core operations."
Supported by an experienced, focused management team, Roberts said it
intends to build upon existing strengths of its prescription pharmaceuticals
which include Pentasa(R), a recently acquired therapy for ulcerative colitis,
plus Agrylin(TM) and ProAmatine(R), the Company's first internally developed
pipeline products and the first FDA cleared drugs, respectively, for essential
thrombocythemia and orthostatic hypotension. These newer high-margin drugs
are now being marketed in the U.S. with Agrylin having also been launched in
Canada earlier this year.
Additionally, the Company noted that Colace(R) has become the fastest
growing non-prescription brand within its category of the U.S. laxative market
and that a separately managed consumer products division will allow for
greater opportunities to further strengthen the prospects of this and other
over-the-counter products such as PeriColace(R) and Slow-Mag(R).
Dr. Gene Emmer has joined Roberts at its Eatontown headquarters as Vice
President and General Manager of the newly created Rx Division and will be
responsible for the U.S. sales force, marketing, and managed care strategies.
Dr. Emmer comes to Roberts from Hoffmann-La Roche AG where he served as Head
of Marketing and Sales, Greece; Product Manager, Switzerland; and most
recently as Director responsible for all Roche HIV/AIDS products for the UK
market. He holds a Ph.D. in physiology from the State University of New York
(Buffalo), an MBA in marketing from MIT's Sloan School of Business, and a B.A.
in physiology from UC Berkeley.
Mr. Richard Caulfield has been appointed to the position of Vice President
and General Manager, Consumer Pharmaceutical Products. In that capacity,
Mr. Caulfield will be responsible for U.S. non-prescription sales and
marketing and the functioning of the Company's distribution center in Buffalo
Grove, Illinois. A nine-year veteran with Roberts, Mr. Caulfield served the
Company as Director and Vice President of Sales and Marketing. Prior to
joining Roberts, he held senior sales and marketing positions at Bristol-Myers
Squibb. Mr. Caulfield received a M.S. degree from Wright State University,
Dayton and a B.A. degree from the University of Cincinnati.
Mr. Gert F. Jurgeneit has joined the Company as General Manager of Roberts
Pharmaceutical Canada. Mr. Jurgeneit possesses a wealth of pharmaceutical
industry experience and prior to joining Roberts served as President of
International Pharma Consultants and Vice President of Marketing for
Wyeth-Ayerst, Canada.
Mr. Art Woodruff has been appointed to the position of Vice President,
Corporate Development. Mr. Woodruff has more than 30 years of pharmaceutical
experience including the past five years with Roberts Pharmaceutical Canada
where he was instrumental in the growth of that subsidiary's operations. Mr.
Woodruff served as Vice President and in senior sales and marketing positions
with Promocare Resources, Wyeth Canada, and Glaxo Canada. He has a B.S.
degree from the University of British Columbia.
Commenting on today's announcement, Dr. Robert A. Vukovich, Roberts'
Founder and Executive Chairman said "These individuals possess an abundance of
expertise which strongly augments our very fine staff of professionals and our
Company's commitment to growth."
Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada and the United Kingdom, focuses on licensing, acquiring,
developing and commercializing innovative pharmaceuticals.
This and past press releases of Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On-Call fax service at
1-800-758-5804, extension 760975 and on the internet at
http://www.prnewswire.com and http://www.robertspharm.com.
This release may contain forward-looking statements which reflect
management's current views of future events and operations. These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action, product pricing,
competitive market conditions, financial data, and other risks or
uncertainties detailed from time to time in Roberts filings with the
Securities and Exchange Commission. These forward-looking statements
represent the Company's judgment as of the date of this release and any
changes in the assumptions or external factors could produce significantly
different results.
SOURCE Roberts Pharmaceuticals Corporation
 back to top
Related links:
http://www.robertspharm.com
CONTACT:
Stuart Z. Levine, Ph.D., Director of Investor
Relations, 732-389-1182, ext. 3064
|
